191 related articles for article (PubMed ID: 24369282)
1. [Anti-sclerostin antibody : its bone formation effect and therapeutic potential for osteoporosis].
Endo I
Clin Calcium; 2014 Jan; 24(1):69-73. PubMed ID: 24369282
[TBL] [Abstract][Full Text] [Related]
2. Sclerostin: a novel target for intervention in the treatment of osteoporosis.
Lewiecki EM
Discov Med; 2011 Oct; 12(65):263-73. PubMed ID: 22031665
[TBL] [Abstract][Full Text] [Related]
3. Anti-sclerostin antibodies: utility in treatment of osteoporosis.
Clarke BL
Maturitas; 2014 Jul; 78(3):199-204. PubMed ID: 24842796
[TBL] [Abstract][Full Text] [Related]
4. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength.
Ominsky MS; Vlasseros F; Jolette J; Smith SY; Stouch B; Doellgast G; Gong J; Gao Y; Cao J; Graham K; Tipton B; Cai J; Deshpande R; Zhou L; Hale MD; Lightwood DJ; Henry AJ; Popplewell AG; Moore AR; Robinson MK; Lacey DL; Simonet WS; Paszty C
J Bone Miner Res; 2010 May; 25(5):948-59. PubMed ID: 20200929
[TBL] [Abstract][Full Text] [Related]
5. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.
Li X; Ominsky MS; Warmington KS; Morony S; Gong J; Cao J; Gao Y; Shalhoub V; Tipton B; Haldankar R; Chen Q; Winters A; Boone T; Geng Z; Niu QT; Ke HZ; Kostenuik PJ; Simonet WS; Lacey DL; Paszty C
J Bone Miner Res; 2009 Apr; 24(4):578-88. PubMed ID: 19049336
[TBL] [Abstract][Full Text] [Related]
6. Sclerostin: therapeutic horizons based upon its actions.
Costa AG; Bilezikian JP
Curr Osteoporos Rep; 2012 Mar; 10(1):64-72. PubMed ID: 22234741
[TBL] [Abstract][Full Text] [Related]
7. [Effect on bone structure and strength by novel anti-osteoporotic agents].
Sone T
Clin Calcium; 2013 Jul; 23(7):1021-6. PubMed ID: 23811591
[TBL] [Abstract][Full Text] [Related]
8. Sclerostin and skeletal health.
Sharifi M; Ereifej L; Lewiecki EM
Rev Endocr Metab Disord; 2015 Jun; 16(2):149-56. PubMed ID: 25669441
[TBL] [Abstract][Full Text] [Related]
9. Sclerostin: recent advances and clinical implications.
Honasoge M; Rao AD; Rao SD
Curr Opin Endocrinol Diabetes Obes; 2014 Dec; 21(6):437-46. PubMed ID: 25333305
[TBL] [Abstract][Full Text] [Related]
10. The potential use of antisclerostin therapy in chronic kidney disease-mineral and bone disorder.
Costa AG; Bilezikian JP; Lewiecki EM
Curr Opin Nephrol Hypertens; 2015 Jul; 24(4):324-9. PubMed ID: 26050118
[TBL] [Abstract][Full Text] [Related]
11. Disruption of Lrp4 function by genetic deletion or pharmacological blockade increases bone mass and serum sclerostin levels.
Chang MK; Kramer I; Huber T; Kinzel B; Guth-Gundel S; Leupin O; Kneissel M
Proc Natl Acad Sci U S A; 2014 Dec; 111(48):E5187-95. PubMed ID: 25404300
[TBL] [Abstract][Full Text] [Related]
12. Role of Wnt signaling and sclerostin in bone and as therapeutic targets in skeletal disorders.
Marini F; Giusti F; Palmini G; Brandi ML
Osteoporos Int; 2023 Feb; 34(2):213-238. PubMed ID: 35982318
[TBL] [Abstract][Full Text] [Related]
13. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation.
Poole KE; van Bezooijen RL; Loveridge N; Hamersma H; Papapoulos SE; Löwik CW; Reeve J
FASEB J; 2005 Nov; 19(13):1842-4. PubMed ID: 16123173
[TBL] [Abstract][Full Text] [Related]
14. [Monoclonal antibodies to sclerostin for the treatment of osteoporosis].
Soen S
Clin Calcium; 2013 Jun; 23(6):884-9. PubMed ID: 23719502
[TBL] [Abstract][Full Text] [Related]
15. Update on romosozumab : a humanized monoclonal antibody to sclerostin.
Costa AG; Bilezikian JP; Lewiecki EM
Expert Opin Biol Ther; 2014 May; 14(5):697-707. PubMed ID: 24665957
[TBL] [Abstract][Full Text] [Related]
16. Targeting sclerostin as potential treatment of osteoporosis.
Papapoulos SE
Ann Rheum Dis; 2011 Mar; 70 Suppl 1():i119-22. PubMed ID: 21339215
[TBL] [Abstract][Full Text] [Related]
17. Does osteocytic SOST suppression mediate PTH bone anabolism?
Kramer I; Keller H; Leupin O; Kneissel M
Trends Endocrinol Metab; 2010 Apr; 21(4):237-44. PubMed ID: 20074973
[TBL] [Abstract][Full Text] [Related]
18. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
[TBL] [Abstract][Full Text] [Related]
19. Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes.
Kim JY; Lee SK; Jo KJ; Song DY; Lim DM; Park KY; Bonewald LF; Kim BJ
Life Sci; 2013 Mar; 92(10):533-40. PubMed ID: 23357248
[TBL] [Abstract][Full Text] [Related]
20. The sclerostin story: from human genetics to the development of novel anabolic treatment for osteoporosis.
Yavropoulou MP; Xygonakis C; Lolou M; Karadimou F; Yovos JG
Hormones (Athens); 2014; 13(4):323-37. PubMed ID: 25555179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
